BioScience Health InnovationsBHIC +6.22%47 Net Current Asset Value is $0.14 as of Mar. 2026, which is 100% below its 10-year median of 607.80. GuruFocus rates BHIC with a GF Score™ of 47/100 and a GF Value™ of $164.84 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 275 Healthcare Providers & Services companies, BioScience Health Innovations ranks worse than 88.73% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioScience Health Innovations's net current asset value per share for the quarter that ended in Mar. 2026 was $0.14.
The historical rank and industry rank for BioScience Health Innovations's Net Current Asset Value or its related term are showing as below:
BHIC'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 15.07 Med: 607.8 Max: 5200
Current: 31.02
During the past 7 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioScience Health Innovations was 5200.00. The lowest was 15.07. And the median was 607.80.
BHIC's Price-to-Net-Current-Asset-Value is ranked worse than 88.73% of 275
companies
in the Healthcare Providers & Services industry
Industry Median: 6.05
vs BHIC: 31.02
BioScience Health Innovations (OTCPK:BHIC) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioScience Health Innovations Net Current Asset Value Related Terms
BioScience Health Innovations Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioScience Health Innovations Net Current Asset Value Chart
BHIC vs SHFH, PETS, SCNX: Net Current Asset Value Comparison
For the Pharmaceutical Retailers subindustry, BioScience Health Innovations's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioScience Health Innovations Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, BioScience Health Innovations's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioScience Health Innovations's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.14 mean?
BioScience Health Innovations (BHIC) has a Net Current Asset Value of $0.14 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioScience Health Innovations and its competitors. This is 100% below median its historical median of 607.80. Over the past decade, BioScience Health Innovations' Net Current Asset Value has ranged from 15.07 to 5,200.00. According to the industry distribution chart, BioScience Health Innovations ranks #244 out of 275 companies in the Healthcare Providers & Services industry, placing it in the top 88.7%.
Is BioScience Health Innovations' Net Current Asset Value too high?
BioScience Health Innovations' current Net Current Asset Value of $0.14 is 100% below median its 10-year median of 607.80. Over the past 10 years, this metric has ranged from a low of 15.07 to a high of 5,200.00. The Healthcare Providers & Services industry median Net Current Asset Value is 6.05. BioScience Health Innovations' value of $0.14 is 97.7% below this industry median. Based on the distribution chart, BioScience Health Innovations ranks #244 out of 275 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, BioScience Health Innovations has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioScience Health Innovations' Net Current Asset Value compare to SHFH and PETS?
According to the Healthcare Providers & Services industry distribution chart, BioScience Health Innovations ranks #244 out of 275 companies for Net Current Asset Value. This places BioScience Health Innovations in the lower half of its industry. The industry median Net Current Asset Value is 6.05. BioScience Health Innovations' value of $0.14 is 97.7% below this benchmark. Historically, BioScience Health Innovations' own Net Current Asset Value has ranged from 15.07 to 5,200.00 over the past decade. While the company's 10-year median is 607.80 vs. the industry median of 6.05, BioScience Health Innovations has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 6.05, based on 275 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioScience Health Innovations's current Net Current Asset Value of $0.14 is 97.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioScience Health Innovations and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 6.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioScience Health Innovations's current Net Current Asset Value is $0.14, which is 100% below median its own 10-year median of 607.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioScience Health Innovations stock overvalued right now?
Based on GuruFocus' analysis, BioScience Health Innovations (BHIC) is currently considered Possible Value Trap. The stock's GF Value™ is $164.84, compared to a current price of $4.34 — trading 97.4% below its estimated fair value. The current Net Current Asset Value is $0.14, which is 100% below median its 10-year median of 607.80 and 97.7% below the Healthcare Providers & Services industry median of 6.05. BioScience Health Innovations' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioScience Health Innovations (BHIC), the current Net Current Asset Value is $0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioScience Health Innovations (BHIC) Overvalued in 2026?
Based on GuruFocus' analysis, BioScience Health Innovations stock appears to be undervalued.
The current stock price of $4.34 is trading 97.4% below its estimated GF Value™ of $164.84.
GuruFocus considers BioScience Health Innovations to be Possible Value Trap.
Key valuation signals for BHIC:
Net Current Asset Value: $0.14 (100% below median its 10-year median of 607.80)
GF Value™: $164.84 vs. price of $4.34 (97.4% below fair value)
Industry Position: 97.7% below the Healthcare Providers & Services median (#244 of 275)
No single metric tells the full story. See the BHIC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioScience Health Innovations Business Description
BioScience Health Innovations Inc is engaged in full-scale operations as a distributor and generates revenue. The company's main business is to sell clinically tested, affordably priced products to naturally battle the onslaught of bacteria and viruses through online sales and various other distribution channels. The company develops, manufactures, and distributes science-backed nutritional supplements and delivery systems targeting cellular health, mitochondrial optimization, hormonal balance, and longevity.
47GF Score
Get the complete analysis for BHIC
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHIC has been successfully added to your 
